On Monday, President Trump enacted a Presidential Order that aims to cut prescription drug prices for Americans by as much as 80%. Dubbed the “most favored nation” pricing policy, this order mandates that drug companies charge domestic consumers the same or less than they would charge people in other developed nations.
For many, this seems just fair. Why should Americans pay two to four times more for the same medication compared to folks in countries like Canada, France, or Japan?
Some might argue, however, that Trump’s executive action isn’t simply an overreaction but rather a necessary correction.
Yet, this price disparity isn’t random; it’s part of a deeper, systemic issue. For years, the U.S. has effectively subsidized access to medications for the rest of the world.
Drug manufacturers make their profits off Americans, while countries like Germany and Belgium benefit from lower prices. In essence, Americans have been footing the bill for international pricing models that favor other countries.
By implementing this executive order, Trump confronts this arrangement head-on. It makes it clear that if pharmaceutical companies charge lower prices abroad, similar rates should apply to the U.S., emphasizing a level playing field without preferential treatment for foreign buyers.
This shift represents a significant change from the typical approach in Washington, which helps explain its appeal to the public. It offers a much-needed sense of accountability in a landscape where Americans are often overcharged for essential medicines. For those struggling to afford insulin or other drugs, this feels like a form of justice.
Questions About the Free Market
However, for those of us who value a free market—and I certainly consider myself one—we must grapple with some uncomfortable questions regarding this executive order.
I generally oppose government intervention in pricing. Past experiences have shown that such efforts often result in distortions and inefficiencies. Take, for instance, Hillary Clinton’s healthcare proposals in the 1990s, which involved significant government involvement that led to shortages in vaccine supplies due to discounted government prices. Where profits dwindle, innovation can suffer.
So, why do I hesitate to fully criticize Trump’s initiative?
Well, we’re no longer in a free market situation. The pharmaceutical industry is already entangled in a web of lobbying, regulation, and insurance intricacies. The notion of an unfettered market is largely a fantasy, with prices shaped more by negotiation than by consumer choice. The average person finds themselves without a voice in this complicated dialogue.
In an environment of such distortion, Trump’s executive order can be seen as a necessary intervention rather than an overreach. It aims to rectify an imbalanced field that has been skewed for too long. The U.S. represents the largest market for medicines worldwide; yet, we have consistently failed to leverage that purchasing power.
While other countries negotiate drug prices, we have stayed on the sidelines. That’s not capitalism; that feels more like surrender.
The Necessity of Confusion
Let me clarify—I am not advocating for long-term price controls. The pitfalls of such measures are well-documented: reduced innovation, fewer options, and increased governmental reliance. But let’s not kid ourselves; what we have now is not a functioning free market. It’s broken—and supporting such a system merely because of ideological commitments isn’t conservatism; it’s simply negligence.
We should closely examine the implications. It’s important to be skeptical. Yet, it must also be recognized that our existing system is unsustainable. Americans are paying inflated prices for prescription drugs, effectively subsidizing the lower costs elsewhere. You can call it many things, but let’s not disguise it as capitalism or fairness. It’s more of a redistribution scheme masquerading as market logic.
Trump identified a crucial problem: America has endured too long under this flawed system. His executive order is a necessary disruption to an arrangement that has failed those it was designed to help.
And that’s when I stopped playing the role of champion.
